Sembrix tablets 40mg, manufactured by Novartis Pharma, contains Asciminib Hydrochloride (YJ code: 4291077F2023, standard: 40mg 1 tablet). This allosteric inhibitor specifically targets the ABL myristoyl pocket of the BCR-ABL1 protein, providing a novel mechanism to overcome resistance in chronic myeloid leukemia (CML). It is used for Philadelphia chromosome-positive (Ph+) CML in chronic phase, including patients with the T315I mutation.
Sembrix tablets 40mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →